{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:07:49Z","timestamp":1786975669535,"version":"build-2736575974"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.36741","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T12:41:09Z","timestamp":1614256869000},"page":"e2036741","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials"],"prefix":"10.1001","volume":"4","author":[{"given":"Bruce A.","family":"Feinberg","sequence":"first","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie E.","family":"Zettler","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Klink","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choo H.","family":"Lee","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Kish","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"issue":"10","key":"zoi201101r2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","article-title":"Use of real-world evidence to support FDA approval of oncology drugs.","volume":"23","author":"Feinberg","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"zoi201101r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2016.10.025","article-title":"Finding the evidence in real-world evidence: moving from data to information to knowledge.","volume":"224","author":"Schilsky","year":"2017","journal-title":"J Am Coll Surg"},{"issue":"9","key":"zoi201101r4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamaoncol.2019.1760","article-title":"surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017.","volume":"5","author":"Zettler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi201101r5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"zoi201101r6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer.","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv Ther"},{"issue":"18","key":"zoi201101r7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2217\/imt-2019-0177","article-title":"Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS =50%) metastatic NSCLC at US oncology practices.","volume":"11","author":"Velcheti","year":"2019","journal-title":"Immunotherapy"},{"issue":"Suppl 5","key":"zoi201101r8","doi-asserted-by":"publisher","first-page":"v651","DOI":"10.1093\/annonc\/mdz260.103","article-title":"Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC).","volume":"30","author":"Ma","year":"2019","journal-title":"Ann Oncol"},{"key":"zoi201101r9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2018.10.028","article-title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo).","volume":"127","author":"Halmos","year":"2019","journal-title":"Lung Cancer"},{"issue":"10S","key":"zoi201101r10","first-page":"P1.01","article-title":"Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.","volume":"14","author":"Doebele","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"25","key":"zoi201101r11","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2217\/fon-2018-0964","article-title":"Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.","volume":"15","author":"Luke","year":"2019","journal-title":"Future Oncol"},{"issue":"34","key":"zoi201101r12","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.2217\/fon-2019-0537","article-title":"Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4\/6 inhibitor therapy.","volume":"15","author":"Mougalian","year":"2019","journal-title":"Future Oncol"},{"issue":"6","key":"zoi201101r13","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s12325-020-01362-6","article-title":"Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States.","volume":"37","author":"Kish","year":"2020","journal-title":"Adv Ther"},{"issue":"27","key":"zoi201101r14","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.2217\/fon-2018-0317","article-title":"Using response evaluation criteria in solid tumors in real-world evidence cancer research.","volume":"14","author":"Feinberg","year":"2018","journal-title":"Future Oncol"},{"issue":"5","key":"zoi201101r15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi201101r16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi201101r17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi201101r18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi201101r19","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi201101r20","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi201101r21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.21037\/atm","article-title":"Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Transl Med"},{"issue":"1","key":"zoi201101r22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1148\/radiol.11111111","article-title":"Independent radiologic review in metastatic colorectal cancer: systematic review and meta-analysis.","volume":"263","author":"Lima","year":"2012","journal-title":"Radiology"},{"issue":"1","key":"zoi201101r23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdp478","article-title":"Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.","volume":"21","author":"Tang","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi201101r25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"zoi201101r26","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1200\/JCO.2018.36.15_suppl.9578","article-title":"Time to treatment failure (TTF) as a potential clinical endpoint in real-world evidence (RWE) studies of melanoma.","volume":"36","author":"Sridhara","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi201101r27","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi201101r28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence.","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi201101r1"},{"key":"zoi201101r24","unstructured":"Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. Accessed January 20, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2776898\/feinberg_2021_oi_201101_1613710255.45739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T12:41:15Z","timestamp":1614256875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2776898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36741","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}